Six blockbusters at heart of Novartis' target for solid growth

3 December 2021

Swiss pharma giant Novartis (NOVN: VX) is confident that its sales total will grow by at least 4% at a compound annual growth rate (CAGR) through 2026, investors were told at an R&D day Thursday.

The firm sees multi-billion dollar sales of six products as being key to this, namely Cosentyx (secukinumab), Entresto (sacubitril/valsartan), Kesimpta (ofatumumab), Zolgensma (onasemnogene abeparvovec, Kisqali (ribociclib) and Leqvio (inclisiran).

"Novartis remains disciplined and shareholder focused in its capital allocation priorities"Behind these, Novartis believes that it has 20 new assets with at least $1billion dollar sales potential, that are set to potentially be approved by 2026 and could fuel further growth through 2030 and beyond.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK